A deep sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections

Nicole Mideo, Jeffrey A Bailey, Nicholas J Hathaway, Billy Ngasala, David L Saunders, Chanthap Lon, Oksana Kharabora, Andrew Jamnik, Sujata Balasubramanian, Anders Björkman, Andreas Mårtensson, Steven R Meshnick, Andrew F Read, Jonathan J Juliano, Nicole Mideo, Jeffrey A Bailey, Nicholas J Hathaway, Billy Ngasala, David L Saunders, Chanthap Lon, Oksana Kharabora, Andrew Jamnik, Sujata Balasubramanian, Anders Björkman, Andreas Mårtensson, Steven R Meshnick, Andrew F Read, Jonathan J Juliano

Abstract

Background and objectives: Current tools struggle to detect drug-resistant malaria parasites when infections contain multiple parasite clones, which is the norm in high transmission settings in Africa. Our aim was to develop and apply an approach for detecting resistance that overcomes the challenges of polyclonal infections without requiring a genetic marker for resistance.

Methodology: Clinical samples from patients treated with artemisinin combination therapy were collected from Tanzania and Cambodia. By deeply sequencing a hypervariable locus, we quantified the relative abundance of parasite subpopulations (defined by haplotypes of that locus) within infections and revealed evolutionary dynamics during treatment. Slow clearance is a phenotypic, clinical marker of artemisinin resistance; we analyzed variation in clearance rates within infections by fitting parasite clearance curves to subpopulation data.

Results: In Tanzania, we found substantial variation in clearance rates within individual patients. Some parasite subpopulations cleared as slowly as resistant parasites observed in Cambodia. We evaluated possible explanations for these data, including resistance to drugs. Assuming slow clearance was a stable phenotype of subpopulations, simulations predicted that modest increases in their frequency could substantially increase time to cure.

Conclusions and implications: By characterizing parasite subpopulations within patients, our method can detect rare, slow clearing parasites in vivo whose phenotypic effects would otherwise be masked. Since our approach can be applied to polyclonal infections even when the genetics underlying resistance are unknown, it could aid in monitoring the emergence of artemisinin resistance. Our application to Tanzanian samples uncovers rare subpopulations with worrying phenotypes for closer examination.

Keywords: amplicon sequencing; artemisinin; drug resistance; ecology; malaria; within-host selection.

© The Author(s) 2016. Published by Oxford University Press on behalf of the Foundation for Evolution, Medicine, and Public Health.

Figures

Figure 1.
Figure 1.
Clearance curves and determination of ‘clones’ by deep sequencing. Predicted relative abundances (A) and clearance curves (B) for hypothetical infections composed of sensitive (black, 3-h half-life) and resistant (gray, 6.5-h half life) parasite clones after drug treatment. The initial frequency of the resistant clone is 25% in the top row and 1% in the bottom row. In (B), the dotted line shows the standard parasite clearance curve, as fitted to the total parasite density. The half-life estimates from these curves, for the whole infection, are ∼5.5 h (top) and ∼4 h (bottom). When the resistant clone is rare it exerts little effect on the overall estimate of parasite half-life
Figure 2.
Figure 2.
Schematic of library preparation for highly multiplexed amplicon deep sequencing. (A) Samples are amplified using primers targeting conserved sequences (black fragments) surrounding variable regions (colored fragments). The forward primer contains a barcode (MID) specific to the sample and replicate. (B) After amplification, each PCR reaction contains amplicons representing the haplotypes within that sample labeled with the specific MID. (C) Multiple samples are then mixed forming a final library containing multiple MIDs (white, blue, purple and brown) for preparation for sequencing. This mixture is library prepped with a specific index placed on the library during the process. Multiple libraries with different indexes can then be pooled and sequenced at the same time allowing for highly multiplexed sequencing
Figure 3.
Figure 3.
Deep sequencing of control mixtures. The detected haplotype frequencies of the dilution series are shown, with parasitemias ranging from three genomic equivalents per microliter (GE/µl) to 1536 GE/µl. Each point represents the mean (dot) and 1 SD (error bars) of triplicate experiments. Each experiment involves two PCR replicates used to call haplotypes with a fixed minimum cutoff frequency of 0.5% using SeekDeep. Overall, there is little variation in the frequency estimates within a concentration and between concentrations. Beginning at 24 GE/µl, false-positive haplotypes begin to be detected. Plotted here is the sum total frequency of false haplotypes (red line). Individual samples could contain between 1 and 4 false haplotypes, which individually never exceeded 6% within a single experiment
Figure 4.
Figure 4.
Estimating subpopulation clearance curves from infections in Tanzania. (A) Relative abundance of different parasite subpopulations (defined by haplotypes) within patients. For each patient (row), there are two bar graphs representing technical replicates, labeled 1 and 2. Within each patient, individual subpopulations have specific colors and are ranked by initial frequency. (The same color may thus represent different haplotypes in different patients.) (B) Densities of individual subpopulations (points) are calculated as the total density by quantitative PCR (crosses) multiplied by their relative abundance. Clearance curves are plotted for the total parasite density (dashed lines) and individual subpopulations (colored lines). Statistics reported represent model comparisons; P values < 0.05 indicate that a more complicated model that includes different slopes for each subpopulation within a patient explains significantly more variation than a model with a single slope. Similar plots for 12 additional patients for whom parasites could not be detected at 72 h by PCR can be found in the Supplementary Figs S2 and S3
Figure 5.
Figure 5.
Estimating subpopulation clearance curves from infections in Cambodia. (A) Relative abundance of different parasite subpopulations (defined by haplotypes) within patients. (B) Densities of individual subpopulations (points) are calculated as the total density by PCR (crosses) multiplied by their relative abundance. Clearance curves are plotted for the total parasite density (dashed lines) and individual subpopulations (colored lines)
Figure 6.
Figure 6.
Genetic relationships between parasite haplotypes in one Tanzanian patient. Pseudo minimum spanning tree figure showing the number of nucleotide differences (red dots) between haplotypes (circles) with the minimum number of mismatches and their ties shown to include all haplotypes in the graph for patient T40. Haplotypes are colored as in Fig. 3 (second row from the bottom) and the size of the circle corresponds to the relative abundance of that haplotype at (A) 0 h, (B) 24 h, (C) 48 h and (D) 72 h after the start of drug treatment. Across time points, the total area of the circles is constant
Figure 7.
Figure 7.
Predicted effects on clearance time (by PCR) of increasing the initial frequency of the slowest clearing parasite subpopulation in individual infections. (A) The predicted effects on five of the patients from Tanzania in which significant variation in clearance rates was observed. One patient is plotted on its own (B) for visibility. (Note that the simulations assume that all relevant rates remain constant, i.e. there are no changes in pharmacokinetics/pharmacodynamics nor other within-host processes, over the relevant timescale. This is likely to be violated over the span of 100 days but does not affect our inference of having detected some very slow clearing subpopulations.)
Figure 8.
Figure 8.
Comparison of clearance slopes of parasites isolated from patients in Tanzania (patient IDs beginning with T) and Cambodia (patient IDs beginning with C). For patients from Tanzania, in which significant variation in clearance rates was observed, the predicted clearance slopes ±1 standard error of individual subpopulations are given in different colors. There was no significant variation in infections from Cambodia. The dashed lines (shaded region) represent the mean (±1 standard error of the mean) clearance slopes of patients from each region, as estimated by fitting linear models to the decline in loge total parasite density

References

    1. World Health Organization. World Malaria Report 2014. (2 June 2015, date last accessed).
    1. Amaratunga C, Sreng S, Suon S. et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis 2012;12:851–8.
    1. Ashley EA, Dhorda M, Fairhurst RM. et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2014;371:411–23.
    1. Dondorp AM, Nosten F, Yi P. et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009;361:455–67.
    1. Dondorp AM, Yeung S, White L. et al. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol 2010;8:272–80.
    1. Phyo AP, Nkhoma S, Stepniewska K. et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012;379:1960–6.
    1. Mideo N, Kennedy DA, Carlton JM. et al. Ahead of the curve: next generation estimators of drug resistance in malaria infections. Trends Parasitol 2013;29:321–8.
    1. Ariey F, Witkowski B, Amaratunga C. et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 2014;505:50–5.
    1. Witkowski B, Amaratunga C, Khim N. et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect Dis 2013;13:1043–9.
    1. Kamau E, Campino S, Amenga-Etego L. et al. K13-propeller polymorphisms in Plasmodium falciparum parasites from sub-Saharan Africa. J Infect Dis 2015;211:1352–5.
    1. Taylor SM, Parobek CM, DeConti DK. et al. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in sub-Saharan Africa: a molecular epidemiologic study. J Infect Dis 2015;211:680–8.
    1. Straimer J, Gnadig NF, Witkowski B. et al. Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science 2015;347:428–31.
    1. Miotto O, Amato R, Ashley EA. et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nature Genet 2015;47:226–34.
    1. Andriantsoanirina V, Ratsimbasoa A, Bouchier C. et al. Chloroquine clinical failures in P. falciparum malaria are associated with mutant Pfmdr-1, not Pfcrt in Madagascar. PLoS One 2010;5:e13281.
    1. Ngalah BS, Ingasia LA, Cheruiyot AC. et al. Analysis of major genome loci underlying artemisinin resistance and pfmdr1 copy number in pre- and post-ACTs in western Kenya. Sci Rep 2015;5:8308.
    1. Henriques G, van Schalkwyk DA. et al. The mu subunit of Plasmodium falciparum clathrin-associated adapter protein 2 modulates in vitro parasite response to artemisnin and quinine. Antimicrob Agents Chemother 2015;59:2540–7.
    1. Henriques G, Martinelli A, Rodrigues L. et al. Artemisinin resistance in rodent malaria-mutation in the AP2 adaptor mu-chain suggests involvement of endocytosis and membrane protein trafficking. Malaria J 2013;12:118.
    1. Karunajeewa HA. Parasite clearance after malaria therapy: staying a step ahead of drug resistance. BMC Med 2015;13:251.
    1. Flegg JA, Guerin PJ, White NJ. et al. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J 2011;10:339.
    1. White NJ. The parasite clearance curve. Malar J 2011;10:278.
    1. Hott A, Casandra D, Sparks KN. et al. Artemisinin-resistant Plasmodium falciparum exhibit altered patterns of development in infected erythrocytes. Antimicrob Agents Chemother 2015;59:3156–67.
    1. Bailey JA, Mvalo T, Aragam N. et al. Use of massively parallel pyrosequencing to evaluate the diversity of and selection on Plasmodium falciparum csp T-cell epitopes in Lilongwe, Malawi. J Infect Dis 2012;206:580–7.
    1. Jafari S, Le Bras J, Bouchaud O. et al. Plasmodium falciparum clonal population dynamics during malaria treatment. J Infect Dis 2004;189:195–203.
    1. Juliano JJ, Kwiek JJ, Cappell K. et al. Minority-variant pfcrt K76T mutations and chloroquine resistance, Malawi. Emerg Infect Dis 2007;13:872–7.
    1. Juliano JJ, Porter K, Mwapasa V. et al. Exposing malaria in-host diversity and estimating population diversity by capture-recapture using massively parallel pyrosequencing. Proc Natl Acad Sci USA 2010;107:20138–43.
    1. Zhong D, Afrane Y, Githeko A. et al. Molecular epidemiology of drug-resistant malaria in western Kenya highlands. BMC Infect Dis 2008;8:105.
    1. Taylor SM, Parobek CM, Aragam N. et al. Pooled deep sequencing of Plasmodium falciparum isolates: an efficient and scalable tool to quantify prevailing malaria drug-resistance genotypes. J Infect Dis 2013;208:1998–2006.
    1. Assefa SA, Preston MD, Campino S. et al. estMOI: estimating multiplicity of infection using parasite deep sequencing data. Bioinformatics 2014;30:1292–4.
    1. Lon C, Manning JE, Vanachayangkul P. et al. Efficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in northern Cambodia: an open-label randomized trial. PLoS One 2014;9:e93138.
    1. Carlsson AM, Ngasala BE, Dahlstrom S. et al. Plasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment in Tanzanian children with acute uncomplicated malaria. Malar J 2011;10:380.
    1. Parobek CM, Bailey JA, Hathaway NJ. et al. Differing patterns of selection and geospatial genetic diversity within two leading Plasmodium vivax candidate vaccine antigens. PLoS Negl Trop Dis 2014;8:e2796.
    1. Strain MC, Lada SM, Luong T. et al. Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One 2013;8:e55943.
    1. Beshir KB, Hallett RL, Eziefula AC. et al. Measuring the efficacy of anti-malarial drugs in vivo: quantitative PCR measurement of parasite clearance. Malar J 2010;9:312.
    1. Pickard AL, Wongsrichanalai C, Purfield A. et al. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob Agents Chemother 2003;47:2418–23.
    1. Zuur AF, Ieno EN, Walker NJ. et al. 2009. Mixed Effects Models and Extensions in Ecology with R. New York: Springer Science and Business Media.
    1. Pollitt LC, Reece SE, Mideo N. et al. The problem of auto-correlation in parasitology. PLoS Pathog 2012;8:e1002590.
    1. Lin JT, Hathaway NJ, Saunders DL. et al. Using amplicon deep sequencing to detect genetic signatures of Plasmodium vivax relapse. J Infect Dis 2015;212:999–1008.
    1. Aragam NR, Thayer KM, Nge N. et al. Diversity of T cell epitopes in Plasmodium falciparum circumsporozoite protein likely due to protein-protein interactions. PLoS One 2013;8:e62427.
    1. WWARN Artemisinin based Combination Therapy (ACT) Africa Baseline Study Group. Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated malaria: a meta-analysis of individual patient data. BMC Med 2015;13:212.
    1. Hastings IM, Kay K, Hodel EM. How robust are malaria parasite clearance rates as indicators of drug effectiveness and resistance? Antimicrob Agents Chemother 2015;59:6428–36.
    1. President’s Malaria Initiative. President’s Malaria Initiative Tanzania Malaria Operational Plan FY 2015 (2 June 2015, date last accessed).
    1. Pollitt LC, Sim D, Salathé R. et al. Understanding genetic variation in in vivo tolerance to artesunate: implications for treatment efficacy and resistance monitoring. Evol Appl 2015;8:296–304.
    1. Beshir KB, Sutherland CJ, Sawa P. et al. Residual Plasmodium falciparum parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence. J Infect Dis 2013;208:2017–24.
    1. Chang H-H, Hartl DL. Recurrent bottlenecks in the malaria life cycle obscure signals of positive selection. Parasitology 2015;142:S98–S107.
    1. Molina-Cruz A, Garver LS, Alabaster A. et al. The human malaria parasite Pfs47 gene mediates evasion of the mosquito immune system. Science 2013;340:984–7.

Source: PubMed

3
Prenumerera